BOSTON, Jan. 08, 2026 -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed...
CoLucid Pharmaceuticals Announces Pricing of Initial Public Offering
News | 05. 06. 2015
CoLucid Pharmaceuticals
BURLINGTON, Mass., May 6, 2015 – CoLucid Pharmaceuticals, Inc. ("CoLucid") (CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, announced today the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $10.00 per share.
